ArriVent BioPharma, Inc. Common Stock (AVBP) quarterly balance sheet — complete assets, liabilities & equity history
| Total Current Assets | 348.7M | 332.9M | 321.22M | 250.15M | 185.78M | 226.98M | 292.4M | 308.51M | 327.48M | 159.97M | 179.98M | 198.69M |
| Cash & Short-Term Investments | 326.38M | 312.82M | 300.27M | 235.69M | 176.08M | 218.86M | 282.86M | 298.67M | 317.39M | 150.39M | 166.36M | 182.83M |
| Cash Only | 62.1M | 45.54M | 112.67M | 112.77M | 49.87M | 74.29M | 282.86M | 298.67M | 317.39M | 150.39M | 141.36M | 157.83M |
| Short-Term Investments | 264.28M | 267.28M | 187.59M | 122.92M | 126.21M | 144.57M | 0 | 0 | 0 | 0 | 25M | 25M |
| Accounts Receivable | 0 | 0 | 505K | 505K | 505K | 500K | 500K | 750K | 875K | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 22.32M | 20.08M | 20.45M | 13.96M | 9.2M | 0 | 8.59M | 8.35M | 0 | 9.21M | 13.33M | 15.42M |
| Total Non-Current Assets | 595K | 272K | 5.34M | 19.36M | 29.71M | 47.96M | 313K | 344K | 358K | 3.13M | 2.01M | 158K |
| Property, Plant & Equipment | 370K | 13K | 49K | 85K | 120K | 154K | 187K | 219K | 250K | 291K | 44K | 76K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 5.11M | 18.79M | 29.41M | 47.68M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 225K | 259K | 180K | 479K | 176K | 126K | 126K | 125K | 108K | 2.84M | 1.96M | 82K |
| Total Assets | 349.3M | 333.17M | 326.56M | 269.51M | 215.5M | 274.94M | 292.71M | 308.86M | 327.84M | 163.1M | 181.99M | 198.84M |
| Asset Turnover | - | - | - | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 62.09% | 21.18% | 11.56% | -12.74% | -34.27% | 68.57% | 60.84% | 55.33% | - | -10.79% | - | - |
| Total Current Liabilities | 25M | 25.95M | 21.56M | 19.64M | 12.95M | 17.27M | 15.16M | 12.1M | 9.98M | 11.62M | 10.1M | 12.81M |
| Accounts Payable | 8.73M | 5.93M | 5.93M | 4.06M | 4.36M | 3.78M | 4.65M | 3.81M | 4.1M | 4.53M | 4.82M | 6.46M |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 99K | 14K | 56K | 0 | 0 | 0 | 157K | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 16.17M | 20M | 11.18M | 2.79M | 1.55M | 4.16M | -140K | 2.04M | 1.03M | 0 | 0 | 0 |
| Current Ratio | 13.95x | 12.83x | 14.90x | 12.74x | 14.34x | 13.14x | 19.28x | 25.50x | 32.82x | 13.76x | 17.82x | 15.51x |
| Quick Ratio | 13.95x | 12.83x | 14.90x | 12.74x | 14.34x | 13.14x | 19.28x | 25.50x | 32.82x | 13.76x | 17.82x | 15.51x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 320K | 0 | 0 | 0 | 0 | 14K | 56K | 98K | 138K | 177K | 0 | 0 |
| Long-Term Debt | 320K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 14K | 56K | 98K | 138K | 177K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 25.32M | 25.95M | 21.56M | 19.64M | 12.95M | 17.29M | 15.22M | 12.2M | 10.12M | 11.8M | 10.1M | 12.81M |
| Total Debt | 419K | 14K | 56K | 98K | 138K | 176K | 353K | 250K | 285K | 317K | 44K | 76K |
| Net Debt | -61.68M | -45.53M | -112.62M | -112.67M | -49.73M | -74.12M | -282.5M | -298.42M | -317.11M | -150.07M | -141.31M | -157.76M |
| Debt / Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 323.98M | 307.22M | 305M | 249.87M | 202.54M | 257.65M | 277.49M | 296.66M | 317.72M | 151.3M | 171.89M | 186.03M |
| Equity Growth % | 59.96% | 19.24% | 9.91% | -15.77% | -36.25% | 70.3% | 61.44% | 59.47% | - | -13.28% | - | - |
| Book Value per Share | 7.19 | 7.99 | 7.28 | 7.14 | 5.97 | 7.67 | 8.26 | 8.85 | 9.49 | 4.52 | 5.13 | 5.55 |
| Total Shareholders' Equity | 323.98M | 307.22M | 305M | 249.87M | 202.54M | 257.65M | 277.49M | 296.66M | 317.72M | 151.3M | 171.89M | 186.03M |
| Common Stock | 5K | 4K | 4K | 4K | 4K | 3K | 3K | 3K | 3K | 0 | 4K | 4K |
| Retained Earnings | -447.96M | -404.64M | -369.1M | -334.12M | -302.72M | -238.33M | -217.7M | -197.14M | -175.26M | -157.84M | -136.65M | -122.25M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -270K | 14K | 206K | -18K | -17K | -211K | 0 | 0 | 0 | 0 | -106K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |